Evidence map›Paper›PMID 36579996›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2022

Quercetin Effects on Cell Cycle Arrest and Apoptosis and Doxorubicin Activity in T47D Cancer Stem Cells.

Ebrahim Azizi, Shamileh Fouladdel, Tahereh Komeili Movahhed, Farzan Modaresi, Elmira Barzegar, Mohammad H Ghahremani, Seyed Naser Ostad, Shekoufeh Atashpour

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. A Bioinformatic Assay of Quercetin in Gastric Cancer.International journal of molecular sciences · 2024
    Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Ebrahim AziziDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Shamileh FouladdelDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Tahereh Komeili MovahhedCellular and Molecular Research Center, Qom University of Medical Sciences, Qom, Iran.
Farzan ModaresiDepartments of Microbiology, Advanced Medical Sciences and Technology,Jahrom University of Medical Sciences, Jahrom, Iran.
Elmira BarzegarDepartment of Pharmacology and Toxicology, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Mohammad H GhahremaniDepartment of Pharmacology and Toxicology, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Seyed Naser OstadDepartment of Pharmacology and Toxicology, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Shekoufeh AtashpourDepartment of Pharmacology, Jahrom University of Medical Sciences, Jahrom, Iran.ORCID 0000-0003-2777-1131
University of Michigan–Ann Arbor · USJahrom University of Medical Sciences · IRQom University of Medical Science and Health Services · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundsTargeting breast cancer stem cells with the CD44+/CD24- phenotype is critical for complete eradication of cancer cells due to its Self-renewal, differentiation, and therapeutic resistance ability. Quercetin is a popular flavonoid with lower adverse effects and has anti-tumor properties. Therefore, we assessed the anticancer activity of Quercetin and Doxorubicin alone and in combination in the T47D cells of human breast cancer and their isolated Cancer stem cells (CSCs). MATERIALS AND

methodsThe human breast cancer cell line T47D was used for this experiment. T47D CSCs were isolated by magnetic bead sorting using the MACS system. The anticancer activity of Quercetin and Doxorubicin alone and in combination were evaluated using MTT cytotoxicity assay and cell cycle distribution and apoptosis induction by flow cytometry analysis.

resultsWe have shown that almost 1% of T47D cell populations are made up of CD44+/CD24- cells, which considered as cancer stem cells. Quercetin and Doxorubicin alone or in combination inhibited cell proliferation and induced apoptosis in breast cancer T47D cells and in lower extent in CD44+/CD24- cells. Quercetin significantly strengthened Doxorubicin's cytotoxicity and apoptosis induction in both cell populations. Quercetin and Doxorubicin and their combination induced G2/M arrest in the T47D cells and to a lesser extent in isolated CSCs. A value of p < 0.05 was considered as indicating a statistically significant difference.

conclusionThese outcomes suggested that CSCs are a minor population of cancer cells, which play a significant role in drug resistance by being quiescent, slow cycling and resistance to apoptosis. Furthermore, our data showed that adding Quercetin to Doxorubicin is an effective approach for the treatment of both CSCs and bulk tumor cells.

Indexed as

Breast NeoplasmsQuercetinApoptosisCell CycleCell Cycle CheckpointsCell Line, TumorCell ProliferationDoxorubicinFemaleG2 Phase Cell Cycle CheckpointsHumansNeoplastic Stem CellsDoxorubicinQuercetinApoptosisBreast Cancer cellsCancer stem cellsDrug resistanceQuercetin

Identifiers

PMID36579996
PMCPMC9971456
OpenAlexW4313329104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.